Cargando…

Renoprotective effects of incretin‐based drugs: A novel pleiotropic effect of dipeptidyl peptidase‐4 inhibitor

Renoprotective effects of incretin‐based drug. [Image: see text]

Detalles Bibliográficos
Autores principales:	Kodera, Ryo, Shikata, Kenichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2015
Materias:	Commentaries
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4718108/ https://www.ncbi.nlm.nih.gov/pubmed/26816598 http://dx.doi.org/10.1111/jdi.12380

Ejemplares similares

Renoprotective Effect of a Dipeptidyl Peptidase-4 Inhibitor on Aging Mice
por: Ban, Tae H, et al.
Publicado: (2019)

Renoprotective Effect of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus
por: Esaki, Hiroki, et al.
Publicado: (2017)

Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes
por: Mega, Cristina, et al.
Publicado: (2017)

Visfatin and resistin: Mediators of the pleiotropic effects of incretins?
por: Nakashima, Eitaro
Publicado: (2012)

Renoprotective effects of a dipeptidyl peptidase 4 inhibitor in a mouse model of progressive renal fibrosis
por: Uchida, Takahiro, et al.
Publicado: (2017)

Renoprotective Effect of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, in Streptozotocin-Induced Type 1 Diabetic Mice
por: Jung, Gwon-Soo, et al.
Publicado: (2016)

Dipeptidyl peptidase‐4 inhibitors and prevention of bone fractures: Effects beyond glyemic control
por: Yabe, Daisuke, et al.
Publicado: (2012)

Bullous pemphigoid with dipeptidyl peptidase‐4 inhibitors: Clinical features and pathophysiology
por: Murakami, Takaaki, et al.
Publicado: (2019)

Pleiotropic effects of incretins
por: Gupta, Vishal
Publicado: (2012)

Dipeptidyl Peptidase IV Inhibition Exerts Renoprotective Effects in Rats with Established Heart Failure
por: Arruda-Junior, Daniel F., et al.
Publicado: (2016)

Combined effect of sodium–glucose cotransporter 2 and dipeptidyl peptidase‐4 inhibitors for diabetic kidney disease
por: Araki, Shin‐ichi
Publicado: (2019)

Renoprotection Provided by Dipeptidyl Peptidase-4 Inhibitors in Combination with Angiotensin Receptor Blockers in Patients with Type 2 Diabetic Nephropathy
por: Qiu, Dan-Dan, et al.
Publicado: (2018)

Preventive Effect of Dipeptidyl Peptidase-4 Inhibitor on Atherosclerosis Is Mainly Attributable to Incretin's Actions in Nondiabetic and Diabetic Apolipoprotein E-Null Mice
por: Terasaki, Michishige, et al.
Publicado: (2013)

Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Outcome
por: Kim, Kwang-il
Publicado: (2018)

Potential linkage between dipeptidyl peptidase‐4 inhibitor use and the risk of pancreatitis/pancreatic cancer
por: Shirakawa, Jun, et al.
Publicado: (2020)

Dipeptidyl peptidase-4 inhibitors: Novel mechanism of actions
por: Singh, Awadhesh Kumar
Publicado: (2014)

Renoprotective Effects of Incretin-Based Therapy in Diabetes Mellitus
por: Yaribeygi, Habib, et al.
Publicado: (2021)

The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
por: Kanasaki, Keizo
Publicado: (2018)

Serum and Adipose Dipeptidyl Peptidase 4 in Cardiovascular Surgery Patients: Influence of Dipeptidyl Peptidase 4 Inhibitors
por: Shibasaki, Ikuko, et al.
Publicado: (2022)

Effect of switching to teneligliptin from other dipeptidyl peptidase‐4 inhibitors on glucose control and renoprotection in type 2 diabetes patients with diabetic kidney disease
por: Kitada, Munehiro, et al.
Publicado: (2018)

Correction: The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
por: Kanasaki, Keizo
Publicado: (2019)

New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
por: Cui, Chenkai, et al.
Publicado: (2022)

The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors
por: Kim, Na-Hyung, et al.
Publicado: (2014)

Collagenous Colitis Possibly Associated with Dipeptidyl Peptidase-4 Inhibitor
por: Takedomi, Hironobu, et al.
Publicado: (2022)

Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients
por: Shao, Shih-Chieh, et al.
Publicado: (2020)

Cardiovascular surrogate markers and cardiometabolic therapeutics: a viewpoint learned from clinical trials on dipeptidyl peptidase-4 inhibitors
por: Tanaka, Atsushi, et al.
Publicado: (2021)

Synergistic effect of α‐glucosidase inhibitors and dipeptidyl peptidase 4 inhibitor treatment
por: Horikawa, Yukio, et al.
Publicado: (2010)

Drug fever and acute inflammation from hypercytokinemia triggered by dipeptidyl peptidase‐4 inhibitor vildagliptin
por: Anno, Takatoshi, et al.
Publicado: (2018)

Incretin therapies: highlighting common features and differences in the modes of action of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors
por: Nauck, M.
Publicado: (2016)

Health economic evaluation of dipeptidyl peptidase-4 inhibitors
por: Garg, Vishvas
Publicado: (2011)

Navigating the chemical space of dipeptidyl peptidase-4 inhibitors
por: Shoombuatong, Watshara, et al.
Publicado: (2015)

Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid
por: Tasanen, Kaisa, et al.
Publicado: (2019)

Dipeptidyl peptidase 4 inhibitors: Applications in innate immunity?
por: Yazbeck, R., et al.
Publicado: (2021)

Role of Dipeptidyl Peptidase 4 Inhibitors in Antidiabetic Treatment
por: Yin, Ruili, et al.
Publicado: (2022)

C-Peptide Levels Predict the Effectiveness of Dipeptidyl Peptidase-4 Inhibitor Therapy
por: Demir, Sevin, et al.
Publicado: (2016)

Dipeptidyl peptidase-4 inhibitors have adverse effects for the proliferation of human T cells
por: Kitagawa, Noriyuki, et al.
Publicado: (2018)

Effect of Dipeptidyl Peptidase-4 Inhibitors on Bone Metabolism and the Possible Underlying Mechanisms
por: Yang, Yinqiu, et al.
Publicado: (2017)

Dipeptidyl Peptidase-4 Inhibitors and Bone Fractures: A meta-analysis of randomized clinical trials
por: Monami, Matteo, et al.
Publicado: (2011)

Increasing Age Associated with Higher Dipeptidyl Peptidase-4 Inhibition Rate Is a Predictive Factor for Efficacy of Dipeptidyl Peptidase-4 Inhibitors
por: Hong, Sangmo, et al.
Publicado: (2022)

Long‐term effect of dipeptidyl peptidase‐4 inhibition on β‐cell mass in an advanced‐aged diet‐induced obesity mouse model
por: Yamane, Shunsuke, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_aqp977ceibuja15hik1sjuesvt